Podchaser Logo
Home
The Young Ophthalmologist Perspective

The Young Ophthalmologist Perspective

Released Tuesday, 25th August 2020
Good episode? Give it some love!
The Young Ophthalmologist Perspective

The Young Ophthalmologist Perspective

The Young Ophthalmologist Perspective

The Young Ophthalmologist Perspective

Tuesday, 25th August 2020
Good episode? Give it some love!
Rate Episode

In this interview with Joseph Nezgoda, MD, MBA, we discuss young ophthalmologists – or YOs – and the most important challenges this group faces. Nezgoda also provides his insight and advice for YOs embarking on their career.

  • Intro :13
  • In this episode :15
  • About Dr. Nezgoda :23
  • The interview :54
  • Who is Dr. Nezgoda? 1:29
  • “Ah-ha” moments 4:13
  • What is a young ophthalmologist, or YO? 8:07
  • What is the most important topic or challenge currently facing YOs? 9:57
  • What’s the ideal path – academic, private practice, or a hybrid? 11:41
  • How did you get involved in advocacy? 16:24
  • What do you think will be the biggest challenge for YOs in the future? 22:42
  • Any last advice for YOs starting their career? 26:53
  • Thanks for listening! 29:35

Joseph Nezgoda, MD, MBA, is an ophthalmologist and retina specialist in private practice at Retina Macula Institute in West Palm Beach, Fla. He is also vice president of education at Florida Society of Ophthalmology; editor of ONE Network Retina, American Academy of Ophthalmology; and delegate to the AMA, American Society of Retina Specialists.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Nezgoda reports no relevant financial disclosures.

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Dr. Nezgoda can be reached via www.retinamacula.org

Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features